{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:51:25Z","timestamp":1791697885858,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2020.12.017","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:57:40Z","timestamp":1611748660000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen"],"prefix":"10.1016","volume":"76","author":[{"given":"Scott S.","family":"Sutton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-0097","authenticated-orcid":false,"given":"Joseph","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"H. Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.12.017_bib0195","series-title":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Department of Health and Human Services","year":"2019"},{"issue":"11","key":"10.1016\/j.therap.2020.12.017_bib0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.therap.2020.12.017_bib0205","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"issue":"9987","key":"10.1016\/j.therap.2020.12.017_bib0210","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0215","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ","volume":"3","author":"Gallant","year":"2016","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0220","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.therap.2020.12.017_bib0225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"issue":"19","key":"10.1016\/j.therap.2020.12.017_bib0230","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0235","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.therap.2020.12.017_bib0240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1545109708323132","article-title":"Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART","volume":"7","author":"Fielden","year":"2008","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"1","key":"10.1016\/j.therap.2020.12.017_bib0245","doi-asserted-by":"crossref","first-page":"e0147821","DOI":"10.1371\/journal.pone.0147821","article-title":"Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States","volume":"11","author":"Sweet","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2020.12.017_bib0250","first-page":"570316","article-title":"Single tablet regimen usage and efficacy in the treatment of HIV infection in Australia","volume":"2015","author":"Armstrong","year":"2015","journal-title":"AIDS Res Treat"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0255","first-page":"242","article-title":"Single-versus multiple-tablet HIV regimens: adherence and hospitalization risk","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.therap.2020.12.017_bib0260","doi-asserted-by":"crossref","first-page":"e0170661","DOI":"10.1371\/journal.pone.0170661","article-title":"Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy\u00a0\u2013\u00a0Results from a large French multicenter cohort study","volume":"12","author":"Cotte","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.therap.2020.12.017_bib0265","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/apc.2017.0081","article-title":"Relationship between single tablet antiretroviral, regimen and adherence to medications, and non-antiretroviral patients, among Veterans\u2019 affairs patients with human immunodeficiency virus","volume":"31","author":"Yager","year":"2017","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"10.1016\/j.therap.2020.12.017_bib0270","doi-asserted-by":"crossref","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States","volume":"7","author":"Sax","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0275","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/phar.1728","article-title":"Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy","volume":"36","author":"Scott Sutton","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"42","key":"10.1016\/j.therap.2020.12.017_bib0285","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","article-title":"Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens","volume":"94","author":"Clay","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2020.12.017_bib0290","series-title":"Health Resource and Service Administration. Guide for HIV\/AIDS clinical care","author":"U.S. Department of Health and Human Services HR","year":"2014"},{"issue":"9","key":"10.1016\/j.therap.2020.12.017_bib0295","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.12.017_bib0300","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"7\u20138","key":"10.1016\/j.therap.2020.12.017_bib0305","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.therap.2020.12.017_bib0310","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/phar.1889","article-title":"Odds of viral suppression by regimen type and adherence level in HIV\/AIDS patients receiving antiretroviral therapy","volume":"37","author":"Sutton","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"4 Suppl. 3","key":"10.1016\/j.therap.2020.12.017_bib0315","doi-asserted-by":"crossref","first-page":"19537","DOI":"10.7448\/IAS.17.4.19537","article-title":"Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment","volume":"17","author":"Sweet","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.therap.2020.12.017_bib0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.therap.2020.12.017_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.therap.2020.12.017_bib0330","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jama.300.5.520","article-title":"Estimation of HIV incidence in the United States","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.therap.2020.12.017_bib0335","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1258\/0956462042563666","article-title":"Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death","volume":"15","author":"Kitahata","year":"2004","journal-title":"Int J STD AIDS"},{"issue":"10","key":"10.1016\/j.therap.2020.12.017_bib0340","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350\u00d710(9) cells\/L","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.therap.2020.12.017_bib0345","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.therap.2020.12.017_bib0350","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/323201","article-title":"Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring","volume":"33","author":"Arnsten","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0355","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002030-200003100-00008","article-title":"Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population","volume":"14","author":"Bangsberg","year":"2000","journal-title":"AIDS"},{"issue":"18","key":"10.1016\/j.therap.2020.12.017_bib0360","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"issue":"15","key":"10.1016\/j.therap.2020.12.017_bib0365","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1517\/14656560903176446","article-title":"New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir","volume":"10","author":"Hughes","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0370","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0000000000000643","article-title":"Adherence and HIV RNA suppression in the current era of Highly Active Antiretroviral Therapy (HAART)","volume":"69","author":"Viswanathan","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.therap.2020.12.017_bib0375","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","article-title":"Level of adherence and HIV RNA suppression in the current era of Highly Active Antiretroviral Therapy (HAART)","volume":"19","author":"Viswanathan","year":"2015","journal-title":"AIDS Behav"},{"issue":"7","key":"10.1016\/j.therap.2020.12.017_bib0380","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/apc.2014.0165","article-title":"Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types","volume":"29","author":"Gordon","year":"2015","journal-title":"AIDS Patient Care STDS"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:40Z","timestamp":1758567340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0040595721000639"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.017","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}